Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats

Journal of Neuroimmunology

Volumn 68, Issue 1-2, 1996, Pages 1-11

  Jung, Stefan ^a   Zielasek, Jürgen ^a   Köllner, Gabriele ^a   Donhauser, Torsten ^a   Toyka, Klaus ^a   Hartung, Hans Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Enzyme inhibitor; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Phosphodiesterase; Tumor necrosis factor

Indexed keywords

MYELIN BASIC PROTEIN; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DOWN REGULATION; DRUG THERAPY; ETIOLOGY; FEMALE; MACROPHAGE; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

EID: 0030219022     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-5728(96)00051-3     Document Type: Article

References (53)

1. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:1992;323-329.
2. Alonso A., Carvalho J., Alonso-Torre S.R., Nunez L., Boska L., Crespo M.S. Nitric oxide synthesis in rat peritoneal macrophages is induced by IgE/DNP complexes and cyclic AMP analogues. Evidence in favor of a common signaling mechanism. J. Immunol. 154:1995;6475-6483.
3. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmac. Sci. 11:1990;150-155.
4. Bromberg J.S., Chavin K.D., Kunkel S.L. Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J. Immunol. 148:1992;3412-3417.
5. Cavender D., Saegusa Y., Ziff M. Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor. J. Immunol. 139:1987;1855-1860.
6. Corti A., Poiesi C., Merli S., Cassani G. Tumor necrosis factor (TNF) alpha quantification by ELISA and bioassay: effects of TNF alpha-soluble TNF receptor (p55) complex dissociation during assay incubations. J. Immunol. Methods. 177:1994;191-198.
7. Cross A.H., Misko T.P., Lin R.F., Hickey W.F., Trotter J.L., Tilton R.G. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93:1994;2684-2690.
8. Derian C.K., Santulli R.J., Rao P.E., Solomon H.F., Barrett J.A. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol. 154:1995;308-317.
9. Eylar E.H., Kniskern P.J., Jackson J.J. Myelin basic proteins. Methods Enzymol. 32:1971;323-341.
10. Fabian R.H., Rea H.C. Neuronal toxicity by macrophages in mixed brain cell culture is augmented by antineuronal IgG and dependent upon nitric oxide synthesis. J. Neuroimmunol. 44:1993;95-102.
11. Genain C.P., Roberts T., Davis R.L., Nguyen M.-H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA. 92:1995;3601-3605.
12. Griswold D.E., Webb E.F., Breton J., White J.R., Marshall P.J., Torphy T.J. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation. 17:1993;333-344.
13. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172:1990;391-394.
14. Hartung H.P., Jung S., Stoll G., Zielasek J., Schmidt B., Archelos J.J., Toyka K.V. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J. Neuroimmunol. 40:1992;197-210.
15. Heber-Katz E. The ups and downs of EAE. Int. Rev. Immunol. 9:1993;277-285.
16. Ichimura M., Kase H. A new cyclic nucleotide phosphodiesterase isoenzyme expressed in the T-lymphocyte cell lines. Biochem. Biophy. Res. Commun. 193:1993;985-990.
17. Josaki K., Contrino J., Kristie J., Krause P., Kreutzer D.L. Pentoxifylline-induced modulation of human leukocyte function in vitro. Am. J. Pathol. 136:1990;623-630.
18. Jung S., Schluesener H.J., Schmidt B., Fontana A., Toyka K.V., Hartung H.P. Therapeutic effect of transforming growth factor-β2 on actively induced experimental autoimmune neuritis (EAN) but not on adoptive transfer EAN. Immunology. 83:1994;545-551.
19. Jung S., Schluesener H.J., Toyka K., Hartung H.P. T cell vaccination does not induce resistance to experimental autoimmune neuritis. J. Neuroimmunol. 35:1991;1-11.
20. Jung S., Toyka K., Hartung H.P. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur. J. Immunol. 25:1995;1391-1398.
21. Kammer G.A. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today. 9:1988;222-229.
22. MacMicking J.D., Willenborg D.O., Weidemann M.J., Rockett K.A., Cowden W.D. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis: enhancement by the soluble products of encephalitogenic T cells. J. Exp. Med. 176:1992;303-307.
23. Merrill J.E., Ignarro L.J., Sherman M.P., Melinek J., Lane T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151:1993;2132-2141.
24. Myers, L.W., Ellison, G.W., Merrill, J.E., Leake, B.D., ElHajjar, A., St. Pierre, Granger, D., Fahey, J., Bentson, J. and Tourtelotte, W. (1995) Pentoxifylline not a promising treatment for multiple sclerosis. Neurology 45 (Suppl. 4), A419-419.
25. Nataf S., Louboutin J.P., Chabannes D., Feve J.R., Muller J.Y. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol. Scand. 88:1993;97-99.
26. Novak T.J., Rothenberg E. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc. Natl. Acad. Sci. USA. 87:1990;9353-9357.
27. 2. J. Immunol. 152:1994;5703-5713.
28. Oppenheimer-Marks N., Ziff M. Migration of lymphocytes through endothelial cell monolayers: augmentation by interferongamma. Cell. Immunol. 114:1988;307-323.
29. Pober J.S., Slowik M.R., De Luca L.G., Ritchie A.J. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J. Immunol. 150:1993;5114-5123.
30. Raine, C.S. (1992) Demyelinating diseases. In: R.L. Davis and D.M. Robertson (Eds.), Textbook of Neuropathology, Williams and Wilkins, Baltimore, MD, pp. 535-552.
31. Rice G.C., Brown P.A., Nelson R.J., Bianco J.A., Singer J.W., Bursten S. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc. Natl. Acad. Sci. USA. 91:1994;3857-3861.
32. Rieckmann, P., Weber, F., Günther, A., Bitsch, A., Broocks, A., Kitze, B., Weber, T., Börner, T., Von Eick, H. and Poser, S. (1995) Pentoxifylline for treatment of multiple sclerosis: Therapeutic rationale and first clinical results of a placebo-controlled clinical trial. J. Neurology 242 (Suppl. 2), S112-112.
33. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., Polson J.B. Multiple high-affinity cAMP phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42:1991;869-877.
34. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1993;1745-1751.
35. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
36. Ruuls S.R., Van Der Linden S., Sontrop K., Huitinga I., Dijkstra C.D. Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. Clin. Exp. Immunol. 103:1995;467-474.
37. Schade F.U., Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 230:1993;9-14.
38. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56:1995;135-141.
39. Selmaj K., Raine C.S., Cross A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:1991;694-700.
40. Sheehan K.C.F., Ruddle N.H., Schreiber R.D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factor. J. Immunol. 142:1989;3884-3893.
41. Sinha B., Semmler J., Eisenhut T., Eigler A., Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25:1995;147-153.
42. Sommer N., Löschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmüller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med. 1:1995;244-248.
43. Suttorp N., Weber U., Welsch T., Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J. Clin. Invest. 91:1993;1421-1428.
44. Thanhauser A., Reiling N., Bohle A., Toellner K.M., Duchrow M., Scheel D., Schluter C., Ernst M., Flad H.D., Ulmer A.J. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology. 80:1993;151-156.
45. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 46:1991;512-523.
46. Valitutti S., Dessing M., Lanzavecchia A. Role of cAMP in regulating cytotoxic T lymphocyte adhesion and motility. Eur. J. Immunol. 23:1993;790-795.
47. 2. Inflammation. 5:1981;81-87.
48. Van Oosten, E.W., Rep, M.H.G., Van Lier, R.A.W., Von Blomberg, B.M.E. and Polman, C.H. (1995) Effect of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J. Neurology 242 (Suppl. 2), S119-120.
49. Waage A., Sorensen M., Stordal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet. 335:1990;543.
50. Wachtel H. Potential antidepressant activity of Rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 22:1983;367-372.
51. Wekerle H. Experimental autoimmune encephalomyelitis as a model of immune-mediated CNS disease. Curr. Opin. Neurobiol. 3:1993;779-784.
52. Zielasek J., Jung S., Gold R., Liew F.Y., Toyka K.V., Hartung H.-P. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58:1995;81-88.
53. Zielasek J., Tausch M., Toyka K.V., Hartung H.-P. Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell. Immunol. 141:1992;111-120.